What happens if I need to stop the treatment before it is complete?
If for any reason you need to stop the treatment before it is complete, press and hold the on/off button of the controller for a second. Once turned off completely and when you are ready to restart it, press and hold the on/off button for a second again. The treatment will restart. Now you should inhale and exhale through the mouthpiece as before.
How and when should I replace the Zirela nebulizer?
The Zirela handheld nebulizer should be used for a treatment cycle of 28days. Consult the information on cleaning and storage in the instructions for use of the manufacturer.
If I use more Quinsair than I should
If you have used more Quinsair than you should,inform your doctor as soon as possible. If you swallow the contents of the ampoule, do not worry, but inform your doctor as soon as possible.
If I forget to use Quinsair
If you forget a dose, administer it as soon as you remember, as long as there is a gap of 8hours until the next dose. If it is almost time for the next dose, skip the missed dose.
Do not inhale the contents of more than one ampoule to compensate for the missed dose.
If I interrupt the treatment with Quinsair
Do not stop using Quinsair without consulting your doctor first, as your lung infection may worsen.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Some side effects can be serious
If you notice asevere allergic reactionafter inhaling Quinsair, seekimmediate medical attention. Symptoms include:
Stop using Quinsair and contact your doctor immediately:
Other possible side effects:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
The following side effects have also been reported after taking tablets or receiving an intravenous infusion containing levofloxacin, so they may appear after using Quinsair:
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Unknown frequency: cannot be estimated from available data
The administration of antibiotics containing quinolones and fluoroquinolones has been associated with very rare cases of long-term or permanent adverse reactions (even months or years after treatment), such as tendon inflammation, tendon rupture, joint pain, limb pain, difficulty walking, abnormal sensations, such as pinching, tingling, itching, burning, numbness, or pain (neuropathy), depression, fatigue, sleep disorders, memory impairment, and hearing, vision, taste, and smell impairment, in some cases regardless of pre-existing risk factors.
Reporting of adverse reactions
If you experience any type of adverse reaction, consult your doctor or pharmacist, even if it is a possible adverse reaction that does not appear in this prospectus.You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Usehttps://www.notificaRAM.eshttps://www.notificaRAM.es. By reporting adverse reactions, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the vial, paper envelope, and box after CAD. The expiration date is the last day of the month indicated.
Each vial is only for single use. Once the vial is opened, the contents must be used immediately. Any unused product must be discarded. Return unused vials to the paper envelope to protect them from light.
Store in the original packaging to protect it from light. This medication does not require any special storage temperature.
Medications should not be thrown away through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Composition of Quinsair
Appearance of the product and contents of the package
Quinsair is a transparent, pale yellow solution for inhalation by nebulizer.
The medication is prepared in small plastic vials of 3 ml. There are four sealed vials in each paper envelope, and each box contains 14 envelopes.
Each Quinsair package for 28 days contains a box of 56 (14 envelopes of 4) vials and a box containing a Zirela handheld nebulizer with the manufacturer's usage instructions.
The vial is only labeled in Spanish. The information that appears on the vial is:
On the front of the vial
Quinsair 240 mg
Inhalation solution for nebulizer
Levofloxacin
Inhalation route2.4 ml
On the "wavy zone" on both sides of the vial
LOT
CAD
Marketing authorization holder
Chiesi Farmaceutici S.p.A.
Via Palermo, 26/A
43122 Parma
Italy
Responsible for manufacturing
Adare Pharmaceuticals S.r.l.
Via Martin Luther King, 13
20060 Pessano con Bornago (MI)
Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Chiesi sa/nv Tel: + 32 (0)2 788 42 00 | Lithuania Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073919 |
Bulgaria Chiesi Bulgaria EOOD Phone: + 359 29201205 | Luxembourg Chiesi sa/nv Tel: + 32 (0)2 788 42 00 |
Czech Republic Chiesi CZ s.r.o. Tel: + 420 261221745 | Hungary Chiesi Hungary Kft. Tel.: + 36-1-429 1060 |
Denmark Chiesi Pharma AB Tel: + 46 8 753 35 20 | Malta Chiesi Farmaceutici S.p.A. Tel: + 39 0521 2791 |
Germany Chiesi GmbH Tel: + 49 40 89724-0 | Netherlands Chiesi Pharmaceuticals B.V. Tel: + 31 88 501 64 00 |
Estonia Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073919 | Norway Chiesi Pharma AB Tel: + 46 8 753 35 20 |
Greece Chiesi Hellas AEBE Phone: + 30 210 6179763 | Austria Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073919 |
Spain Chiesi España, S.A.U. Tel: + 34 93 494 8000 | Poland Chiesi Poland Sp. z.o.o. Tel.: + 48 22 620 1421 |
France Chiesi S.A.S. Tel: +33 1 47688899 | Portugal Chiesi Farmaceutici S.p.A. Tel: + 39 0521 2791 |
Croatia Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073919 | Romania Chiesi Romania S.R.L. Tel: + 40 212023642 |
Ireland Chiesi Farmaceutici S.p.A. Tel: + 39 0521 2791 | Slovenia Chiesi Slovenija d.o.o. Tel: + 386-1-43 00 901 |
Iceland Chiesi Pharma AB Phone: +46 8 753 35 20 | Slovakia Chiesi Slovakia s.r.o. Tel: + 421 259300060 |
Italy Chiesi Italia S.p.A. Tel: + 39 0521 279 | Finland Chiesi Pharma AB Phone: +46 8 753 35 20 |
Cyprus Chiesi Farmaceutici S.p.A. Phone: + 39 0521 2791 | Sweden Chiesi Pharma AB Tel: +46 8 753 35 20 |
Lithuania Chiesi Pharmaceuticals GmbH Tel: + 43 1 4073919 | United Kingdom (Northern Ireland) Chiesi Farmaceutici S.p.A. Tel: + 39 0521 2791 |
Last review date of this leaflet: July 2024.
Other sources of information
Detailed information about this medication is available on the European Medicines Agency website:https://www.ema.europa.eu. There are also links to other websites about rare diseases and orphan drugs.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.